# EDGAR Filing Document

**Accession Number:** 0001875091
**File Stem:** 0001213900-25-114111
**Filing Date:** 2025-11
**Character Count:** 2196
**Document Hash:** 3a5b1b9dd0fe3b8f04767265e9f66081
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-114111.hdr.sgml**: 20260403

**ACCESSION NUMBER**: 0001213900-25-114111

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251124

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NeuroSense Therapeutics Ltd.
- **CENTRAL INDEX KEY:** 0001875091
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 11 HAMENOFIM ST.
- **STREET 2:** BUILDING B
- **CITY:** HERZLIYA
- **STATE:** L3
- **ZIP:** 4672562
- **BUSINESS PHONE:** 972-9-9531142

**MAIL ADDRESS:**
- **STREET 1:** 11 HAMENOFIM ST.
- **STREET 2:** BUILDING B
- **CITY:** HERZLIYA
- **STATE:** L3
- **ZIP:** 4672562

NeuroSense Theapeutics Ltd.

11 HaMenofim Street, Building B

Herzliya 4672562

November 24, 2025

*<u>VIA EDGAR</u>*

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, DC 20549

RE: NeuroSense Therapeutics Ltd. (CIK 0001875091) <br> <u>Registration Statement No. 333-291122 on Form F-3 (the "Registration Statement")</u>

Ladies and Gentlemen:

NeuroSense Therapeutics Ltd. (the "<u>Registrant</u>") hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), so that it may become effective on November 25, 2025 at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.

The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, Greenberg Traurig, P.A., by calling Gary Emmanuel at + 972 (0) 3.636.6033. The Company hereby authorizes Mr. Emmanuel to orally modify or withdraw this request for acceleration.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| NEUROSENSE THERAPEUTICS LTD. | NEUROSENSE THERAPEUTICS LTD. |
| By: | /s/ *Or Eisenberg* |
|  | Or Eisenberg<br> Chief Financial Officer |

---